CytRx (NASDAQ:CYTR) is scheduled to be announcing its earnings results before the market opens on Friday, November 2nd. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
CytRx (NASDAQ:CYTR) last released its earnings results on Monday, August 6th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.08. On average, analysts expect CytRx to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ:CYTR opened at $0.72 on Thursday. CytRx has a 52-week low of $0.65 and a 52-week high of $2.59.
CytRx Company Profile
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies.
Further Reading: Why is the conference call important?
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.